Financial results for second-quarter 2009 announced by Aptilon

Aptilon Corporation ("Aptilon" or the "Company") (TSX-V: APZ), a leader in online marketing to physicians, today announced its financial results for the three and six months ended June 30, 2009. Financial references are in CDN dollars unless otherwise indicated. Complete financial statements and MD&A are available on SEDAR at www.sedar.com.

Q2 2009 Summary

- Revenues reached $3.0 million, compared to $1.65 million in Q2 2008
- Gross profit totaled $2.2 million compared to $922,943 in Q2 2008
- Gross margin was 74% compared to 56% in Q2 2008
- Net loss totaled ($440,862) (including $433,048 in non-cash charges
(1)) compared to ($2.1 million) (including $363,431 in non-cash
charges (1)) in Q2 2008

"We continued to organically grow the business during the second quarter with revenues and gross profit showing sequential growth for the fourth consecutive quarter," said Dr. Roger Korman, Chairman and CEO of Aptilon. "This growth is due in large part to the traction we have earned with our top US pharmaceutical client companies. The access to physicians our multichannel media service offers these pharmaceutical clients is a novel method to engage physicians in meaningful interactions. As these clients recognize the benefit of our AxcelRx(SM) service in the earlier stage pilot projects and single brand programs we are able to transition them to multi-brand and enterprise-level programs. The multi-brand enterprise agreements that we have secured with top US pharmaceutical companies are a long-term source of recurring revenue and future growth. We are now seeing the measurable results of these efforts which will continue in the coming quarters."